Humana reported Q2 revenues of $40.87 billion, up 26.2% year on year, exceeding analysts' expectations by 0.6%. The health insurance provider also beat earnings per share estimates. Despite the relatively strong results, Humana's stock has fallen 2.7% since the earnings announcement and currently trades at $378.11. The health insurance sector as a whole showed resilience in Q2, with the 12 tracked providers beating revenue consensus estimates by 2.8% on average. However, share prices across the sector have declined an average of 5.8% since reporting. Humana derives over 80% of its revenue from federal government contracts and serves approximately 17 million members, with a strong focus on Medicare Advantage plans for seniors.

Nearly 3 million older Americans will lose their Medicare Advantage plans this year, according to Johns Hopkins Bloomberg School of Public Health research. One in 10 Medicare Advantage policyholders face forced disenrollment, with Vermont hit hardest at 92% of policyholders affected. Humana announced its exit from multiple markets for the second consecutive year, impacting 600,000 members. The company reported $1.9 billion profit in the first half of 2026. Insurers cite financial pressures from federal policy changes aimed at reducing overpayments, resulting in lower government reimbursement rates. Combined with rising medical costs, these factors are squeezing profit margins. Shannon Benton of Senior Citizens League said Humana's decision shows Medicare Advantage insurers are "prioritising profit growth over enrollment growth.

Nine pharmacy benefit managers will integrate TrumpRx prescription drug pricing into their benefit tools, effective 1 January 2027. The Pharmaceutical Care Management Association and participating PBMs—including CVS Health, Express Scripts, Humana, and OptumRx—will display cash prices from TrumpRx alongside plan coverage costs. The agreement covers commercial, Medicare, and Medicaid plans. Patients will see TrumpRx prices for all listed drugs, whether through presidential deals or standard pricing. CMS Administrator Dr Mehmet Oz said the commitment will help patients compare prices and find better deals. PCMA CEO David Marin stated the transparency will allow consumers to make better-informed choices about prescription drug costs. Some PBMs will use Real Time Benefit Tools to display pricing comparisons, whilst others may employ different methods.